Altering microbial populations and modifying microbiota

Patent metadata

Field	Value
Publication number	US-12502401-B2
Application number	US-202519030138-A
Country	US
Kind code	B2
Filing date	Jan 17, 2025
Priority date	May 6, 2015
Publication date	Dec 23, 2025
Grant date	Dec 23, 2025

Abstract

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

First claim

What is claimed is:

1 . An engineered bacterial host cell comprising an exogenous nucleic acid encoding a protein,
wherein the engineered bacterial host cell comprises a nucleic acid for producing a crRNA, wherein the nucleic acid for producing the crRNA is an exogenous nucleic acid that is integrated into the genome of the engineered bacterial host cell and is under control of an inducible promoter in the engineered bacterial host cell; wherein the crRNA comprises a nucleic acid sequence that is capable of hybridizing to a chromosomal target nucleotide sequence in the engineered bacterial host cell to guide a Cas protein to modify the chromosomal target nucleotide sequence in the engineered bacterial host cell, wherein the modification of the chromosomal target nucleotide sequence by the Cas protein kills the engineered bacterial host cell.

2 . The engineered bacterial host cell of claim 1 , wherein the crRNA and the Cas are components of a Type I, II, or III CRISPR/Cas system.

3 . The engineered bacterial host cell of claim 1 , wherein the protein is an antibiotic.

4 . The engineered bacterial host cell of claim 1 , wherein the chromosomal target nucleotide sequence is a host cell plasmid sequence.

5 . The engineered bacterial host cell of claim 1 , wherein the crRNA and Cas are components of a Type I CRISPR/Cas system.

6 . The engineered bacterial host cell of claim 1 , wherein the crRNA and Cas are components of a Type II CRISPR/Cas system.

7 . The engineered bacterial host cell of claim 1 , wherein the crRNA and Cas are components of a Type III CRISPR/Cas system.

8 . The engineered bacterial host cell of claim 6 , wherein the Cas is a Cas9.

9 . The engineered bacterial host cell of claim 1 , wherein the crRNA guides the Cas to modify the chromosomal target nucleotide sequence by cutting the chromosomal target nucleotide sequence.

10 . The engineered bacterial host cell of claim 1 , wherein the Cas is a Cas nuclease.

11 . The engineered bacterial host cell of claim 1 , wherein the Cas is a dead Cas.

12 . The engineered bacterial host cell of claim 1 , wherein the Cas is an endogenous Cas of the engineered bacterial host cell.

13 . The engineered bacterial host cell of claim 1 , wherein the Cas is encoded by an exogenous nucleic acid in the engineered bacterial host cell.

Assignees

• Snipr Tech Ltd

Inventors

• Clube Jasper
• Sommer Morten
• Grøndahl Christian
• Van Der Helm Eric
• Vazquez-Uribe Ruben

Classifications

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• C12N2795/00032

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N1/20

  Bacteria; Culture media therefor · CPC title

• A61K48/005

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title